ArticleMolecular biology reports2025
Potential role of pentraxin 3 (PTX3) and aldehyde dehydrogenase (ALDH) in liver cirrhotic patients: predicting and diagnostic impact in hepatocellular carcinoma (HCC) development.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePatients with liver cirrhosis (LC) are at the highest risk of developing hepatocellular carcinoma (HCC). Thus, this research aimed to clarify the tumorigenic potential of PTX3 and ALDH implicated in HCC development and to find a novel diagnostic model for predicting HCC earlier in liver cirrhotic Egyptian patients. PATIENTS AND
methods88 patients hospitalized at Gastrointestinal Surgery Center for liver transplantation; 63 HCV-chronic liver disease patients after successful Direct acting antiviral (DAA) therapy (30 HCC patients on top of LC and 33 LC patients) and 25 Non-viral LC in addition to 25 healthy individuals. PTX3 and ALDH serum levels were estimated by Enzyme linked immunosorbent assay (ELISA).
resultsPTX3, ALDH and AFP were significantly correlated with each other and its higher expression was associated with tumor differentiation and inflammatory markers in HCC patients and with LC activity in HCV-LC. Regression analysis of PTX3, ALDH, AFP and the inflammatory markers (PLR, NLR, AAR, Pt) evidenced substantial prediction for tumor grading, Child score, and LC activity as independent predictors for disease severity and tumor progression. Composite score of PTX3 + AFP + FIB4 exhibit higher diagnostic accuracy for discriminating HCC from LC patients with AUROC (0.872), sensitivity (90%), specificity (87.8%) and Accuracy (88.9%).
conclusionsInflammation and tissue injury might provoke the tumorigenic potential of PTX3 and ALDH in HCV chronic liver diseases foremost HCC development even after successful eradication for HCV. Diagnostic model (PTX3 + AFP + FIB4) showed the best diagnostic accuracy for discriminating HCC from LC patients.
Indexed as
Identifiers
40802153What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.